Market Cap 192.79M
Revenue (ttm) 0.00
Net Income (ttm) -51.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 5.10
Volume 360,500
Avg Vol 79,782
Day's Range N/A - N/A
Shares Out 16.34M
Stochastic %K 81%
Beta 1.18
Analysts Strong Sell
Price Target $12.50

Company Profile

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node–targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node–targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma...

Industry: Biotechnology
Sector: Healthcare
Phone: (857) 209-0050
Website: elicio.com
Address:
451 D Street, 5th Floor Suite 501, Boston, United States
GannAnalysisCapital
GannAnalysisCapital Aug. 23 at 1:22 PM
$ELTX Elicio Therapeutics Inc is a clinical stage oncology company with vaccine platform
0 · Reply
justiceforb_85
justiceforb_85 Aug. 19 at 7:25 PM
$ELTX holding strong. Impressed there hasn't been an offering (though wouldn't blame the company if they did).
4 · Reply
Woooehoo
Woooehoo Aug. 19 at 12:39 PM
$ELTX needs one big randomized DFS win in Q4 and then there is no reason this isn’t at least a $B market cap
0 · Reply
RealtorNewYork
RealtorNewYork Aug. 19 at 12:26 AM
$ELTX The study was sponsored and funded by Elicio Therapeutics, the Massachusetts company that developed the vaccine. Mutations in the KRAS gene are responsible for half of colorectal cancers and more than 90% of pancreatic cancers. The vaccine, which targets those mutations, was given via a series of injections to activate an immune response in the lymph nodes. A majority (21 out of 25) of the patients generated "KRAS-specific T cells," which indicates a stronger immune response. The ones with higher T-cell responses showed a longer relapse-free survival compared to those with lower responses, the researchers found. For three colorectal cancer patients and three pancreatic cancer patients, the vaccine appeared to remove all disease biomarkers.
0 · Reply
RealtorNewYork
RealtorNewYork Aug. 19 at 12:19 AM
$ELTX BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the publication of follow-up data from the Phase 1 AMPLIFY-201 study evaluating ELI-002 in the peer-reviewed scientific journal, Nature Medicine. The article, entitled, “Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: Phase 1 AMPLIFY-201 trial final results,” highlights that with extended follow-up, more than two-thirds of participants (17 of 25) whose T cell responses exceeded the antitumor efficacy threshold experienced a significantly reduced risk for relapse or death.
0 · Reply
StockScanners
StockScanners Aug. 19 at 12:17 AM
$ELTX keep watch if this holds above 11.35
0 · Reply
Ms_P
Ms_P Aug. 18 at 4:52 PM
$VRNA Anyone else here looking at $ELTX?
1 · Reply
outlawinvestor1
outlawinvestor1 Aug. 18 at 3:40 PM
$ELTX quick question re: ph2 enrollment. Sorry if this has been asked before, but I’m new to the story. Did the company mention after their Dec 2024 that they kept the enrollment at 144 pts? In their Dec PR, they mention the enrollment was completed with 135 pts. However, the Aug 5 PR interim update mentioned 144 pts.
1 · Reply
TradrVision
TradrVision Aug. 18 at 3:17 PM
$ELTX UTRX insiders don’t get paid unless the stock RIPS 🚀📊 Options strike at $0.50 and only vest with treasury + market cap milestones (held 30 sessions) up to $500M cap 🤯 ALL-IN alignment + thin float + crypto treasury = asymmetric setup. 🎯 PT $0.55-0.60 on breakout
0 · Reply
topstockalerts
topstockalerts Aug. 18 at 3:07 PM
$ELTX let’s see that bounce....
0 · Reply
Latest News on ELTX
Elicio Therapeutics Secures $10 Million in Financing

Jun 4, 2025, 8:00 AM EDT - 2 months ago

Elicio Therapeutics Secures $10 Million in Financing


Elicio Therapeutics Reports Inducement Grants

Oct 16, 2024, 8:30 AM EDT - 11 months ago

Elicio Therapeutics Reports Inducement Grants


Elicio Therapeutics Announces Proposed Public Offering

Jun 27, 2024, 4:05 PM EDT - 1 year ago

Elicio Therapeutics Announces Proposed Public Offering


GannAnalysisCapital
GannAnalysisCapital Aug. 23 at 1:22 PM
$ELTX Elicio Therapeutics Inc is a clinical stage oncology company with vaccine platform
0 · Reply
justiceforb_85
justiceforb_85 Aug. 19 at 7:25 PM
$ELTX holding strong. Impressed there hasn't been an offering (though wouldn't blame the company if they did).
4 · Reply
Woooehoo
Woooehoo Aug. 19 at 12:39 PM
$ELTX needs one big randomized DFS win in Q4 and then there is no reason this isn’t at least a $B market cap
0 · Reply
RealtorNewYork
RealtorNewYork Aug. 19 at 12:26 AM
$ELTX The study was sponsored and funded by Elicio Therapeutics, the Massachusetts company that developed the vaccine. Mutations in the KRAS gene are responsible for half of colorectal cancers and more than 90% of pancreatic cancers. The vaccine, which targets those mutations, was given via a series of injections to activate an immune response in the lymph nodes. A majority (21 out of 25) of the patients generated "KRAS-specific T cells," which indicates a stronger immune response. The ones with higher T-cell responses showed a longer relapse-free survival compared to those with lower responses, the researchers found. For three colorectal cancer patients and three pancreatic cancer patients, the vaccine appeared to remove all disease biomarkers.
0 · Reply
RealtorNewYork
RealtorNewYork Aug. 19 at 12:19 AM
$ELTX BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the publication of follow-up data from the Phase 1 AMPLIFY-201 study evaluating ELI-002 in the peer-reviewed scientific journal, Nature Medicine. The article, entitled, “Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: Phase 1 AMPLIFY-201 trial final results,” highlights that with extended follow-up, more than two-thirds of participants (17 of 25) whose T cell responses exceeded the antitumor efficacy threshold experienced a significantly reduced risk for relapse or death.
0 · Reply
StockScanners
StockScanners Aug. 19 at 12:17 AM
$ELTX keep watch if this holds above 11.35
0 · Reply
Ms_P
Ms_P Aug. 18 at 4:52 PM
$VRNA Anyone else here looking at $ELTX?
1 · Reply
outlawinvestor1
outlawinvestor1 Aug. 18 at 3:40 PM
$ELTX quick question re: ph2 enrollment. Sorry if this has been asked before, but I’m new to the story. Did the company mention after their Dec 2024 that they kept the enrollment at 144 pts? In their Dec PR, they mention the enrollment was completed with 135 pts. However, the Aug 5 PR interim update mentioned 144 pts.
1 · Reply
TradrVision
TradrVision Aug. 18 at 3:17 PM
$ELTX UTRX insiders don’t get paid unless the stock RIPS 🚀📊 Options strike at $0.50 and only vest with treasury + market cap milestones (held 30 sessions) up to $500M cap 🤯 ALL-IN alignment + thin float + crypto treasury = asymmetric setup. 🎯 PT $0.55-0.60 on breakout
0 · Reply
topstockalerts
topstockalerts Aug. 18 at 3:07 PM
$ELTX let’s see that bounce....
0 · Reply
topstockalerts
topstockalerts Aug. 18 at 2:37 PM
$ELTX Stay tuned for more!
0 · Reply
topstockalerts
topstockalerts Aug. 18 at 2:06 PM
$ELTX primed for continuation.. ✅
0 · Reply
Tbone05
Tbone05 Aug. 18 at 2:06 PM
Bought $ELTX last week. I love supporting companies trying to wipe out pancreatic cancer
0 · Reply
Lets_Go_Brndn
Lets_Go_Brndn Aug. 18 at 1:59 PM
1 · Reply
elitechrisvp
elitechrisvp Aug. 18 at 1:55 PM
$ELTX kapow
0 · Reply
topstockalerts
topstockalerts Aug. 18 at 1:34 PM
$ELTX can’t say you weren’t warned.. 🔥 ..
0 · Reply
topstockalerts
topstockalerts Aug. 18 at 12:37 PM
$ELTX waking up.. 🚨🚨 ..
0 · Reply
Woooehoo
Woooehoo Aug. 18 at 12:36 PM
$ELTX does this randomly pre market, goes back to 9
0 · Reply
Doozio
Doozio Aug. 18 at 12:27 PM
$ELTX 🐒🍌🧠⏰♾️
0 · Reply
topstockalerts
topstockalerts Aug. 18 at 12:03 PM
$ELTX here it comes…
0 · Reply
GoVeryLong
GoVeryLong Aug. 18 at 11:41 AM
$ELTX only a matter of time before everyone reads the headlines and jumps in.
1 · Reply
BioTechHealthX
BioTechHealthX Aug. 18 at 11:39 AM
$ELTX Elicio Therapeutics is leading off-the-shelf cancer vax targeting deadly KRAS mutations. This can be the miracle patients have been waiting. https://biotechhealthx.com/biotech-news/elicio-therapeutics-eltx-the-cancer-vaccine-revolution-changing-lives-in-2025/
0 · Reply